Read More

Bruker Corp Preliminary Expectation For Revenue For Q4 2022 To Be Up Low Single Digits % YoY, A Result Of Organic Growth Of Mid-To-High Single Digits % YoY; Initial Guidance For 2023 For Organic Revenue Growth Up Mid-To-High Single Digit % YoY

On January 9, 2023 during its scheduled presentation at the 41st Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for

BRKR

Read More

Royalty Pharma Highlights Accomplishments And Provides Business Update; 2022 Net Cash Provided By Operating Activities Expected To Be ~$2.14B-$2.15B; 2022 Adjusted Cash Receipts Expected To Be ~$2.785B-$2.790B, Towards The Upper End Of Guidance Range

2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts(1) (non-GAAP) expected to be

RPRX

Read More

Alaunos Therapeutics Highlights Strategic Priorities And Anticipated Portfolio Milestones For 2023; Alaunos Ended Q4 2022 With Unaudited Cash And Cash Equivalents Of ~$39.1M And Restricted Cash Of ~$13.9M

Announcing addition of two new TCRs to the library, estimated to double the addressable market; plans to further expand TCR library using hunTR® TCR discovery platform   Increasing patient enrollment to

TCRT